ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020
Molecular Imaging of Cardiac Amyloidosis.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis.BMC cardiovascular disorders · 2021Pooled it
- Preclinical and preliminary clinical evaluation of [European journal of nuclear medicine and molecular imaging · 2026Trial
- Artificial Intelligence in Cardiac Amyloidosis: A State-of-the-Art Review.Journal of clinical medicine · 2026Review
- Transthyretin Cardiac Amyloidosis and Heart Failure: State-of-the-Art Review and Practice Guidance.Reviews in cardiovascular medicine · 2025Review
- Review
- From Molecular to Radionuclide and Pharmacological Aspects in Transthyretin Cardiac Amyloidosis.International journal of molecular sciences · 2024Review
- Diagnostic Modalities in the Detection of Cardiac Amyloidosis.Journal of clinical medicine · 2024Review
- Arrhythmias and Device Therapies in Cardiac Amyloidosis.Journal of clinical medicine · 2024Review
- Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan.ESC heart failure · 2023Article
- Cardiac amyloidosis: state-of-the-art review.Journal of geriatric cardiology : JGC · 2023Article
- Optical molecular imaging and theranostics in neurological diseases based on aggregation-induced emission luminogens.European journal of nuclear medicine and molecular imaging · 2022Review
- Reliability and feasibility of visual grading systems and quantitative indexes on [Scientific reports · 2022Article
- New Advanced Imaging Parameters and Biomarkers-A Step Forward in the Diagnosis and Prognosis of TTR Cardiomyopathy.Journal of clinical medicine · 2022Review
- Article
- Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise.Diagnostics (Basel, Switzerland) · 2021Review
- Review
- Pilot Study of F18-Florbetapir in the Early Evaluation of Cardiac Amyloidosis.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Transthyretin and light-chain amyloidosis are the 2 main causes of cardiac amyloidosis. Recent developments in molecular imaging have transformed our ability to diagnose transthyretin cardiac amyloidosis noninvasively and unmasked a hitherto unrecognized prevalence of the disease. This review summarizes the current and evolving imaging approaches, their molecular structural basis, and the gaps in imaging capabilities that have arisen as a result of parallel developments in pharmacotherapy delivering the first effective treatment options for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.